E-LIB Suche - Ergebnisse für: Cree, B.

1

P.010 Safety and efficacy of inebilizumab in AQP4+ NMOSD pa..:

Paul, F ; Marignier, R ; Lindsey, JW...
Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques. 51 (2024) s1 - p. S17-S17 , 2024

Link: https://doi.org/10.1017/..

2

Association of cytokine proteins with disease activity in N..:

Aktas, O. ; Pittock, S.J. ; Kim, H.J....
Clinical Neurophysiology. 159 (2024) - p. e19 , 2024

Link: https://doi.org/10.1016/..

3

P.009 Long-term comparative efficacy of inebilizumab from N..:

Cree, B ; Suero, B ; Walsh, S...
Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques. 51 (2024) s1 - p. S16-S17 , 2024

Link: https://doi.org/10.1017/..

4

Inebilizumab improves pain outcomes and quality of life in ..:

Paul, F. ; Hartung, H. ; Smith, M...
Clinical Neurophysiology. 159 (2024) - p. e17 , 2024

Link: https://doi.org/10.1016/..

5

P-61 Characterization of subclinical optic nerve magnetic r..:

Paul, F. ; Bennett, J. ; Chen, J....
Clinical Neurophysiology. 148 (2023) - p. e36 , 2023

Link: https://doi.org/10.1016/..

6

P-59 Association of B cell subsets and aquaporin-4 antibody..:

Paul, F. ; Pittock, S. ; Kim, H.J....
Clinical Neurophysiology. 148 (2023) - p. e35 , 2023

Link: https://doi.org/10.1016/..

7

P 4 The impact of low affinity immunoglobulin gamma Fc regi..:

Paul, F. ; Bennett, J. ; Weinshenker, B....
Clinical Neurophysiology. 137 (2022) - p. e16-e17 , 2022

Link: https://doi.org/10.1016/..

8

Longer-term Safety with Siponimod Treatment in Multiple Scl..:

Kappos, L. ; Vermersch, P. ; Fox, R....
Multiple Sclerosis and Related Disorders. 26 (2018) - p. 255-256 , 2018

Link: https://doi.org/10.1016/..

9

Siponimod (BAF312) for the treatment of secondary progressi..:

Kappos, L. ; Bar-Or, A. ; Cree, B....
Multiple Sclerosis and Related Disorders. 3 (2014) 6 - p. 752 , 2014

Link: https://doi.org/10.1016/..

10

Patient preferences for attributes of disease modifying The..:

Wilson, L.S. ; Loucks, A. ; Bui, C.T....
Value in Health. 16 (2013) 3 - p. A107 , 2013

Link: https://doi.org/10.1016/..

11

Effects of a 24-Week Natalizumab Treatment Interruption on ..:

Weinstock-Guttman, B. ; Cree, B. ; De Seze, J....
Neurology. 78 (2012) Meeting Abstracts 1 - p. P06.171-P06.171 , 2012

Link: https://doi.org/10.1212/..

12

T Cells from Patients with Neuromyelitis Optica Recognize D..:

Varrin-Doyer, M. ; Spencer, C. ; Schulze Topphoff, U....
Neurology. 78 (2012) Meeting Abstracts 1 - p. S60.003-S60.003 , 2012

Link: https://doi.org/10.1212/..

13

RESTORE Study: Effects of a 24-Week Natalizumab Treatment I..:

Cree, B. ; De Seze, J. ; Fox, R....
Neurology. 78 (2012) Meeting Abstracts 1 - p. P06.168-P06.168 , 2012

Link: https://doi.org/10.1212/..

14

Association of Targeted Blood Biomarkers with Interferon Be..:

Cree, B. ; Madireddy, L. ; De Stefano, N....
Neurology. 78 (2012) Meeting Abstracts 1 - p. P02.089-P02.089 , 2012

Link: https://doi.org/10.1212/..

15

Quality of life in multiple sclerosis is associated with le..:

Mowry, E. M. ; Beheshtian, A. ; Waubant, E....
Neurology. 72 (2009) 20 - p. 1760-1765 , 2009

Link: https://doi.org/10.1212/..